Pharmaceutical

FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market

Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.

Jun 28, 2024 - 04:00
FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market
Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.
Read the original article

Tags:

Previous Article

Biotech fund Curie.Bio augments reserves with $380m to boost startups  

Next Article

Formation Bio secures $372m funds for AI-driven drug platform

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How orphan designated drugs private equity performed in the pharmaceutical industry in Q2 2023

How orphan designated drugs private equity performed in...

Jul 21, 2023

STAT+: Biden invokes Defense Production Act to stem drug shortages

STAT+: Biden invokes Defense Production Act to stem dru...

Nov 29, 2023

Medicxi and Starpharma to develop dendrimer-based cancer treatments

Medicxi and Starpharma to develop dendrimer-based cance...

Apr 9, 2024